Literature DB >> 11704701

Clinical aspects of hypertensive myocardial fibrosis.

J Díez1, B López, A González, R Querejeta.   

Abstract

Myocardial fibrosis is one of the histologic constituents of myocardial remodeling present in hypertensive patients with hypertensive heart disease. In fact, an exaggerated interstitial and perivascular accumulation of fibrillar collagens type I and type III has been found in the myocardium of patients with arterial hypertension and left ventricular hypertrophy. Hypertensive myocardial fibrosis has been shown to facilitate abnormalities of cardiac function, coronary reserve, and electrical activity that adversely affect the clinical outcome of hypertensive patients. Therefore, development of noninvasive tools for the monitoring of myocardial fibrosis and pharmacological strategies aimed to promote the regression of fibrosis could be of particular relevance in the clinical treatment of patients with hypertensive heart disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704701     DOI: 10.1097/00001573-200111000-00003

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  28 in total

1.  Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers.

Authors:  Sharon Zlochiver; Viviana Muñoz; Karen L Vikstrom; Steven M Taffet; Omer Berenfeld; José Jalife
Journal:  Biophys J       Date:  2008-07-25       Impact factor: 4.033

2.  Serum concentration of procollagen type III amino-terminal peptide is increased in patients with successfully repaired coarctation of the aorta with left ventricular hypertrophy.

Authors:  Hirokuni Yamazawa; Tomoaki Murakami; Atsuhito Takeda; Kouta Takei; Takuo Furukawa; Hiromichi Nakajima
Journal:  Pediatr Cardiol       Date:  2014-10-14       Impact factor: 1.655

3.  Reduced collagen deposition in infarcted myocardium facilitates induced pluripotent stem cell engraftment and angiomyogenesis for improvement of left ventricular function.

Authors:  Bo Dai; Wei Huang; Meifeng Xu; Ronald W Millard; Mei Hua Gao; H Kirk Hammond; Donald R Menick; Muhammad Ashraf; Yigang Wang
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

4.  Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy.

Authors:  Julio C B Ferreira; Tomoyoshi Koyanagi; Suresh S Palaniyandi; Giovanni Fajardo; Eric N Churchill; Grant Budas; Marie-Helene Disatnik; Daniel Bernstein; Patricia C Brum; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2011-09-02       Impact factor: 5.000

5.  Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.

Authors:  Stephane Heymans; Florea Lupu; Sven Terclavers; Bjorn Vanwetswinkel; Jean-Marc Herbert; Andrew Baker; Desire Collen; Peter Carmeliet; Lieve Moons
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

6.  In vivo quantification of myocardial stiffness in hypertensive porcine hearts using MR elastography.

Authors:  Ria Mazumder; Samuel Schroeder; Xiaokui Mo; Bradley D Clymer; Richard D White; Arunark Kolipaka
Journal:  J Magn Reson Imaging       Date:  2016-08-26       Impact factor: 4.813

Review 7.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

8.  Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice.

Authors:  Ying Ann Chiao; Trevi A Ramirez; Rogelio Zamilpa; S Michelle Okoronkwo; Qiuxia Dai; Jianhua Zhang; Yu-Fang Jin; Merry L Lindsey
Journal:  Cardiovasc Res       Date:  2012-08-22       Impact factor: 10.787

Review 9.  Fibrosis and heart failure.

Authors:  Ana Maria Segura; O H Frazier; L Maximilian Buja
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

10.  Atrophic cardiomyocyte signaling in hypertensive heart disease.

Authors:  German Kamalov; Wenyuan Zhao; Tieqiang Zhao; Yao Sun; Robert A Ahokas; Tony N Marion; Fahed Al Darazi; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2013-12       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.